Clinical trial
A Phase II Study Evaluating the Efficacy/Safety of Lenalidomide With or Without Epoetin Beta in Transfusion-dependent ESA-resistant Patients With IPSS Low- and Intermediate-1 Risk Myelodysplastic Syndromes Without Chromosome 5 Abnormality.
NCT01718379 is registered in ClinicalTrials.gov with Groupe Francophone des Myelodysplasies as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study Evaluating the Efficacy/Safety of Lenalidomide With or Without Epoetin Beta in Transfusion-dependent ESA-resistant Patients With IPSS Low- and Intermediate-1 Risk Myelodysplastic Syndromes Without Chromosome 5 Abnormality.
- Lead sponsor
- Groupe Francophone des Myelodysplasies
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 31, 2010
- Completion date
- June 30, 2016
- Enrollment
- 132 (actual)
- Sites
- 48
Conditions
As the registry lists them; a condition with its own page is linked.